Cathepsin L1 (Cathepsin L or Major Excreted Protein or CTSL or EC 3.4.22.15) - Pipeline Review, H2 2018
Cathepsin L1 (Cathepsin L or Major Excreted Protein or CTSL or EC 3.4.22.15) - Pipeline Review, H2 2018
SUMMARY
Cathepsin L1 (Cathepsin L or Major Excreted Protein or CTSL or EC 3.4.22.15) pipeline Target constitutes close to 6 molecules. The latest report Cathepsin L1 - Pipeline Review, H2 2018, outlays comprehensive information on the Cathepsin L1 (Cathepsin L or Major Excreted Protein or CTSL or EC 3.4.22.15) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.
Cathepsin L1 (Cathepsin L or Major Excreted Protein or CTSL or EC 3.4.22.15) - Cathepsin L, a lysosomal endopeptidase is a member of the papain-like family of cysteine proteinases. Cathepsin L plays a major role in antigen processing, tumor invasion and metastasis, bone resorption, and turnover of intracellular and secreted proteins involved in growth regulation.
Although commonly recognized as a lysosomal protease, cathepsin L is also secreted. The cathepsin L gene is activated by a variety of growth factors, tumor promoters, and second messengers. Cathepsin L promote tumor cell invasion and metastasis by catalyzing degradation of the interstitial matrix and basement membranes, thus allowing cancer cells to invade locally and metastasize to distant sites. The molecules developed by companies in Phase 0, Preclinical and Discovery stages are 1, 3 and 2 respectively. Report covers products from therapy areas Oncology, Central Nervous System, Gastrointestinal, Immunology and Infectious Disease which include indications Autoimmune Disorders, Breast Cancer, Cancer Pain, Head And Neck Cancer Squamous Cell Carcinoma, Liver Fibrosis, Metastatic Prostate Cancer, Middle East Respiratory Syndrome (MERS), Neuropathic Pain (Neuralgia), Osteosarcoma, Pancreatic Cancer, Primary Biliary Cirrhosis and Severe Acute Respiratory Syndrome (SARS).
Furthermore, this report also reviews key players involved in Cathepsin L1 (Cathepsin L or Major Excreted Protein or CTSL or EC 3.4.22.15) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
SCOPE
SUMMARY
Cathepsin L1 (Cathepsin L or Major Excreted Protein or CTSL or EC 3.4.22.15) pipeline Target constitutes close to 6 molecules. The latest report Cathepsin L1 - Pipeline Review, H2 2018, outlays comprehensive information on the Cathepsin L1 (Cathepsin L or Major Excreted Protein or CTSL or EC 3.4.22.15) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.
Cathepsin L1 (Cathepsin L or Major Excreted Protein or CTSL or EC 3.4.22.15) - Cathepsin L, a lysosomal endopeptidase is a member of the papain-like family of cysteine proteinases. Cathepsin L plays a major role in antigen processing, tumor invasion and metastasis, bone resorption, and turnover of intracellular and secreted proteins involved in growth regulation.
Although commonly recognized as a lysosomal protease, cathepsin L is also secreted. The cathepsin L gene is activated by a variety of growth factors, tumor promoters, and second messengers. Cathepsin L promote tumor cell invasion and metastasis by catalyzing degradation of the interstitial matrix and basement membranes, thus allowing cancer cells to invade locally and metastasize to distant sites. The molecules developed by companies in Phase 0, Preclinical and Discovery stages are 1, 3 and 2 respectively. Report covers products from therapy areas Oncology, Central Nervous System, Gastrointestinal, Immunology and Infectious Disease which include indications Autoimmune Disorders, Breast Cancer, Cancer Pain, Head And Neck Cancer Squamous Cell Carcinoma, Liver Fibrosis, Metastatic Prostate Cancer, Middle East Respiratory Syndrome (MERS), Neuropathic Pain (Neuralgia), Osteosarcoma, Pancreatic Cancer, Primary Biliary Cirrhosis and Severe Acute Respiratory Syndrome (SARS).
Furthermore, this report also reviews key players involved in Cathepsin L1 (Cathepsin L or Major Excreted Protein or CTSL or EC 3.4.22.15) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
SCOPE
- The report provides a snapshot of the global therapeutic landscape for Cathepsin L1 (Cathepsin L or Major Excreted Protein or CTSL or EC 3.4.22.15)
- The report reviews Cathepsin L1 (Cathepsin L or Major Excreted Protein or CTSL or EC 3.4.22.15) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Cathepsin L1 (Cathepsin L or Major Excreted Protein or CTSL or EC 3.4.22.15) targeted therapeutics and enlists all their major and minor projects
- The report assesses Cathepsin L1 (Cathepsin L or Major Excreted Protein or CTSL or EC 3.4.22.15) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Cathepsin L1 (Cathepsin L or Major Excreted Protein or CTSL or EC 3.4.22.15) targeted therapeutics
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Cathepsin L1 (Cathepsin L or Major Excreted Protein or CTSL or EC 3.4.22.15)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Cathepsin L1 (Cathepsin L or Major Excreted Protein or CTSL or EC 3.4.22.15) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Introduction
Global Markets Direct Report Coverage
Cathepsin L1 (Cathepsin L or Major Excreted Protein or CTSL or EC 3.4.22.15) - Overview
Cathepsin L1 (Cathepsin L or Major Excreted Protein or CTSL or EC 3.4.22.15) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Cathepsin L1 (Cathepsin L or Major Excreted Protein or CTSL or EC 3.4.22.15) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Cathepsin L1 (Cathepsin L or Major Excreted Protein or CTSL or EC 3.4.22.15) - Companies Involved in Therapeutics Development
Mateon Therapeutics Inc
Phelix Therapeutics LLC
Virobay Inc
Cathepsin L1 (Cathepsin L or Major Excreted Protein or CTSL or EC 3.4.22.15) - Drug Profiles
Drugs to Inhibit Cathepsin L for Coronaviridae Infections - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
KGP-207 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
KGP-420 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
KGP-94 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
VBY-285 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
VBY-825 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Cathepsin L1 (Cathepsin L or Major Excreted Protein or CTSL or EC 3.4.22.15) - Dormant Products
Cathepsin L1 (Cathepsin L or Major Excreted Protein or CTSL or EC 3.4.22.15) - Product Development Milestones
Featured News & Press Releases
Mar 31, 2017: Mateon Therapeutics Announces Abstract Presentations for the American Association for Cancer Research Annual Meeting in April 2017
Apr 07, 2014: OXiGENE Announces Results of KGP94 Preclinical Studies at 2014 AACR Conference
Mar 27, 2014: OXiGENE Announces Presentation of Preclinical Abstracts at 2014 AACR Conference
Nov 14, 2011: Virobay's Spectrum-Selective Cathepsin Inhibitor Shows Efficacy In Bone Cancer Model
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
Global Markets Direct Report Coverage
Cathepsin L1 (Cathepsin L or Major Excreted Protein or CTSL or EC 3.4.22.15) - Overview
Cathepsin L1 (Cathepsin L or Major Excreted Protein or CTSL or EC 3.4.22.15) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Cathepsin L1 (Cathepsin L or Major Excreted Protein or CTSL or EC 3.4.22.15) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Cathepsin L1 (Cathepsin L or Major Excreted Protein or CTSL or EC 3.4.22.15) - Companies Involved in Therapeutics Development
Mateon Therapeutics Inc
Phelix Therapeutics LLC
Virobay Inc
Cathepsin L1 (Cathepsin L or Major Excreted Protein or CTSL or EC 3.4.22.15) - Drug Profiles
Drugs to Inhibit Cathepsin L for Coronaviridae Infections - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
KGP-207 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
KGP-420 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
KGP-94 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
VBY-285 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
VBY-825 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Cathepsin L1 (Cathepsin L or Major Excreted Protein or CTSL or EC 3.4.22.15) - Dormant Products
Cathepsin L1 (Cathepsin L or Major Excreted Protein or CTSL or EC 3.4.22.15) - Product Development Milestones
Featured News & Press Releases
Mar 31, 2017: Mateon Therapeutics Announces Abstract Presentations for the American Association for Cancer Research Annual Meeting in April 2017
Apr 07, 2014: OXiGENE Announces Results of KGP94 Preclinical Studies at 2014 AACR Conference
Mar 27, 2014: OXiGENE Announces Presentation of Preclinical Abstracts at 2014 AACR Conference
Nov 14, 2011: Virobay's Spectrum-Selective Cathepsin Inhibitor Shows Efficacy In Bone Cancer Model
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
LIST OF TABLES
Number of Products under Development by Stage of Development, H2 2018
Number of Products under Development by Therapy Areas, H2 2018
Number of Products under Development by Indication, H2 2018
Number of Products under Development by Companies, H2 2018
Products under Development by Companies, H2 2018
Number of Products by Stage and Mechanism of Actions, H2 2018
Number of Products by Stage and Route of Administration, H2 2018
Number of Products by Stage and Molecule Type, H2 2018
Pipeline by Mateon Therapeutics Inc, H2 2018
Pipeline by Phelix Therapeutics LLC, H2 2018
Pipeline by Virobay Inc, H2 2018
Dormant Projects, H2 2018
Number of Products under Development by Stage of Development, H2 2018
Number of Products under Development by Therapy Areas, H2 2018
Number of Products under Development by Indication, H2 2018
Number of Products under Development by Companies, H2 2018
Products under Development by Companies, H2 2018
Number of Products by Stage and Mechanism of Actions, H2 2018
Number of Products by Stage and Route of Administration, H2 2018
Number of Products by Stage and Molecule Type, H2 2018
Pipeline by Mateon Therapeutics Inc, H2 2018
Pipeline by Phelix Therapeutics LLC, H2 2018
Pipeline by Virobay Inc, H2 2018
Dormant Projects, H2 2018
LIST OF FIGURES
Number of Products under Development by Stage of Development, H2 2018
Number of Products under Development by Therapy Areas, H2 2018
Number of Products under Development by Top 10 Indications, H2 2018
Number of Products by Stage and Mechanism of Actions, H2 2018
Number of Products by Stage and Route of Administration, H2 2018
Number of Products by Stage and Molecule Type, H2 2018
COMPANIES MENTIONED
Mateon Therapeutics Inc
Phelix Therapeutics LLC
Virobay Inc
Number of Products under Development by Stage of Development, H2 2018
Number of Products under Development by Therapy Areas, H2 2018
Number of Products under Development by Top 10 Indications, H2 2018
Number of Products by Stage and Mechanism of Actions, H2 2018
Number of Products by Stage and Route of Administration, H2 2018
Number of Products by Stage and Molecule Type, H2 2018
COMPANIES MENTIONED
Mateon Therapeutics Inc
Phelix Therapeutics LLC
Virobay Inc
